Persistent effect of tocilizumab in refractory Takayasu’s arteritis (clinical observation)

Study of the interleukin 6 (IL-6) role in chronic autoimmune inflammation has led to the development of innovative treatments for various autoimmune inflammatory rheumatic diseases, including Takayasu’s arteritis (TAK). Given the important role of IL-6 in the pathogenesis of TAK and its association...

Full description

Saved in:
Bibliographic Details
Main Authors: G. M. Koilubaeva, A. Sh. Sarybaev, A. M. Bolotbekova, T. V. Dubinina, E. L. Nasonov, F. S. Dzhuzenova, M. A. Chukubaev, Z. E. Turdukulov, K. A. Dzhailobaeva
Format: Article
Language:Russian
Published: IMA PRESS LLC 2022-05-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/3158
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849400886389899264
author G. M. Koilubaeva
A. Sh. Sarybaev
A. M. Bolotbekova
T. V. Dubinina
E. L. Nasonov
F. S. Dzhuzenova
M. A. Chukubaev
Z. E. Turdukulov
K. A. Dzhailobaeva
author_facet G. M. Koilubaeva
A. Sh. Sarybaev
A. M. Bolotbekova
T. V. Dubinina
E. L. Nasonov
F. S. Dzhuzenova
M. A. Chukubaev
Z. E. Turdukulov
K. A. Dzhailobaeva
author_sort G. M. Koilubaeva
collection DOAJ
description Study of the interleukin 6 (IL-6) role in chronic autoimmune inflammation has led to the development of innovative treatments for various autoimmune inflammatory rheumatic diseases, including Takayasu’s arteritis (TAK). Given the important role of IL-6 in the pathogenesis of TAK and its association with high clinical and laboratory activity of the disease, tocilizumab (TCZ) is recommended as a second-line drug if both glucocorticoids and basic antiinflammatory drugs are inefficient, and previous therapy with tumor necrosis factor-α (alpha) inhibitors. The article presents our own observation of the successful use of TCZ in a patient with refractory TAK.
format Article
id doaj-art-7fef65daed3d46b290496fce4693569b
institution Kabale University
issn 1995-4484
1995-4492
language Russian
publishDate 2022-05-01
publisher IMA PRESS LLC
record_format Article
series Научно-практическая ревматология
spelling doaj-art-7fef65daed3d46b290496fce4693569b2025-08-20T03:37:53ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922022-05-0160224224810.47360/1995-4484-2022-242-2482802Persistent effect of tocilizumab in refractory Takayasu’s arteritis (clinical observation)G. M. Koilubaeva0A. Sh. Sarybaev1A. M. Bolotbekova2T. V. Dubinina3E. L. Nasonov4F. S. Dzhuzenova5M. A. Chukubaev6Z. E. Turdukulov7K. A. Dzhailobaeva8National Center for Cardiology and Therapy named after Academician Mirsaid Mirrakhimov under the Ministry of Health of the Kyrgyz RepublicNational Center for Cardiology and Therapy named after Academician Mirsaid Mirrakhimov under the Ministry of Health of the Kyrgyz RepublicNational Center for Cardiology and Therapy named after Academician Mirsaid Mirrakhimov under the Ministry of Health of the Kyrgyz RepublicV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyNational Center for Cardiology and Therapy named after Academician Mirsaid Mirrakhimov under the Ministry of Health of the Kyrgyz RepublicNational Center for Cardiology and Therapy named after Academician Mirsaid Mirrakhimov under the Ministry of Health of the Kyrgyz RepublicNational Center for Cardiology and Therapy named after Academician Mirsaid Mirrakhimov under the Ministry of Health of the Kyrgyz RepublicB.N. Yeltsin Kyrgyz-Russian Slavic UniversityStudy of the interleukin 6 (IL-6) role in chronic autoimmune inflammation has led to the development of innovative treatments for various autoimmune inflammatory rheumatic diseases, including Takayasu’s arteritis (TAK). Given the important role of IL-6 in the pathogenesis of TAK and its association with high clinical and laboratory activity of the disease, tocilizumab (TCZ) is recommended as a second-line drug if both glucocorticoids and basic antiinflammatory drugs are inefficient, and previous therapy with tumor necrosis factor-α (alpha) inhibitors. The article presents our own observation of the successful use of TCZ in a patient with refractory TAK.https://rsp.mediar-press.net/rsp/article/view/3158takayasu’s arteritisinterleukin 6inflammationtocilizumabrefractorinessactivitystenosis
spellingShingle G. M. Koilubaeva
A. Sh. Sarybaev
A. M. Bolotbekova
T. V. Dubinina
E. L. Nasonov
F. S. Dzhuzenova
M. A. Chukubaev
Z. E. Turdukulov
K. A. Dzhailobaeva
Persistent effect of tocilizumab in refractory Takayasu’s arteritis (clinical observation)
Научно-практическая ревматология
takayasu’s arteritis
interleukin 6
inflammation
tocilizumab
refractoriness
activity
stenosis
title Persistent effect of tocilizumab in refractory Takayasu’s arteritis (clinical observation)
title_full Persistent effect of tocilizumab in refractory Takayasu’s arteritis (clinical observation)
title_fullStr Persistent effect of tocilizumab in refractory Takayasu’s arteritis (clinical observation)
title_full_unstemmed Persistent effect of tocilizumab in refractory Takayasu’s arteritis (clinical observation)
title_short Persistent effect of tocilizumab in refractory Takayasu’s arteritis (clinical observation)
title_sort persistent effect of tocilizumab in refractory takayasu s arteritis clinical observation
topic takayasu’s arteritis
interleukin 6
inflammation
tocilizumab
refractoriness
activity
stenosis
url https://rsp.mediar-press.net/rsp/article/view/3158
work_keys_str_mv AT gmkoilubaeva persistenteffectoftocilizumabinrefractorytakayasusarteritisclinicalobservation
AT ashsarybaev persistenteffectoftocilizumabinrefractorytakayasusarteritisclinicalobservation
AT ambolotbekova persistenteffectoftocilizumabinrefractorytakayasusarteritisclinicalobservation
AT tvdubinina persistenteffectoftocilizumabinrefractorytakayasusarteritisclinicalobservation
AT elnasonov persistenteffectoftocilizumabinrefractorytakayasusarteritisclinicalobservation
AT fsdzhuzenova persistenteffectoftocilizumabinrefractorytakayasusarteritisclinicalobservation
AT machukubaev persistenteffectoftocilizumabinrefractorytakayasusarteritisclinicalobservation
AT zeturdukulov persistenteffectoftocilizumabinrefractorytakayasusarteritisclinicalobservation
AT kadzhailobaeva persistenteffectoftocilizumabinrefractorytakayasusarteritisclinicalobservation